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Background: There is a lack of information regarding the epidemiology of malaria among travellers from non-
malaria endemic countries to Sahelian areas. The literature provides general statistics about imported malaria in
industrialized countries or extensive recommendations about fever management, but none of these recommendations
are applicable to developing countries.
Methods: The aim of the study was to evaluate the aetiologies of fever, malaria prevalence, and best diagnostic
methods in a population of 306 non-malaria endemic travellers who, over a one-year period, consulted the French
embassy’s Centre Médico-Social in Ouagadougou (Burkina Faso) for fever. All patients underwent a clinical examination,
a questionnaire, and three different malaria tests: thick blood film, QBC-test and HRP-2-based rapid diagnostic test.
Results: Fever was caused by malaria in 69 cases (23%), while 37 (12%) were due to Pneumonia and 35 cases (8%) to
ENT infections. Fever remained unexplained in 87 patients (51.3%). Malaria prevalence varied throughout the year:
about 90% of malaria cases were diagnosed during and after the rainy season, between July and December, with up to
50% malaria prevalence for fever cases in October. Malaria diagnosis based solely on clinical signs, combined or not,
leads to about 80% of unnecessary treatments.Although anti-malarial chemoprophylaxis was used in only 69% of short-
stay patients (who travelled for less than three months), this was effective. Under local conditions, and using blood film
examination as the reference method, the QBC test appeared to be more reliable than the HRP-2-based rapid
diagnostic test, with respective sensitivities of 98.6% versus 84.1%, and specificities of 99.6% versus 98.3%.
Conclusions: Reliable biological diagnosis of malaria among travellers from non-malaria endemic countries in Sahelian
areas is necessary because of low malaria prevalence and the poor performance of clinical diagnosis. A fever during the
first half of the year requires investigating another aetiology, particularly a respiratory one. Malaria chemoprophylaxis is
efficient and must not be overlooked. The QBC test appears to be the most reliable diagnostic test in this context.
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In Burkina Faso, a Sahelian country in West Africa, ma-
laria transmission is holoendemic, with a very low perman-
ent transmission and a very strong seasonal component
[1-4]. Each year, there are approximately 1,5 million ma-
laria cases and 40,000 victims; 90% of them are children
under 15 years of age [5-7]. Approximately 20,000 French
people travel to Burkina Faso each year, and 3,200 settle
there permanently [8].* Correspondence: stephschrot@gmail.com; candolfi@unistra.fr
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distribution, and reproduction in any mediumThere are some general statistics regarding malaria im-
portation in industrialized countries. With a general
prevalence for malaria in sub-Saharan Africa travellers of
one to four per 1,000 [9,10], the prevalence of fever due
to malaria after travelling to a tropical country is quite
variable, ranging from 27% to 52% [11-15], and malaria
among patients consulting in Europe after a travel in
sub-Saharan Africa is 20% in 2009 [16]. However, this
data was collected in hospitals or specialist settings, or
from a specific population. The different ”tropical” desti-
nations, though varied, were not specifically identified in
these studies. Burkina Faso often appeared in the “sub-
Saharan Africa” category, which brought together sanitaryCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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areas. The literature provides different recommendations
about fever management and malaria suspicion after trav-
elling to a tropical country [17-20]. These recommenda-
tions are very extensive, but are not applicable to a
developing country, where physicians are rare and tests
not always available or reliable: if malaria diagnosis is un-
problematic in Europe, where laboratories are required to
provide a diagnosis within 2 hours, the same cannot be
said for malaria diagnosis in endemic countries [21-31].
Then, the only safe solution for patients is to use an
“Emergency Standby Treatment for Malaria” [32].
But a medical structure must be able to establish a re-
liable diagnosis and trust its own assays.
The aim of this study was to determine malaria preva-
lence and other main aetiologies of fever among febrile
patients from non-malaria endemic countries, according
to the length of their stay in Burkina Faso. Microscopic
quantitative buffy coat test (QBC), which was used dur-
ing consultations, was compared to the non-microscopic
rapid diagnostic test (RDT), which targets the histidine-
rich protein-2 (HRP2) of Plasmodium falciparum.
Methods
Inclusion criteria
This study was conducted at the French embassy’s Centre
Médico-Social (CMS) in Ouagadougou (Burkina Faso).
This is a small primary health centre that treats predomin-
ately French embassy staff and travellers living in or pass-
ing through Burkina Faso and coming from non-malaria
endemic countries. From this population, patients over 15
years of age who had spent the first five years of their life
outside of a malaria-endemic area and had “suspicion of
malaria” between July 2006 and July 2007 were recruited.
“Suspicion of malaria” was defined as “febrile syndrome”
in the last 48 hours, for fever remained the most sensible
clinical sign of malaria [33,34]. “Febrile syndrome” was de-
fined as an uncorrected axillary temperature over 37.5 °C,
as measured at the air-conditioned CMS, at home, or by
acute febrile signs including shivers, hot flashes, and
sweating.
Data collection
During the consultation, an oral consent was informed
for each patient. A questionnaire was completed with
the patient with the following information:
– Malaria chemoprophylaxis;
– Anti-malarial and antipyretic treatment taken over
the last few days;
– Travels outside Burkina Faso over the last few weeks.
All patients underwent an examination. Uncorrected ax-
illary temperature of each patient prior to the clinicalexamination was measured. Patients with temperature
above 38.0°C were considered as “febrile on examination”.
Using a sterile lancet, blood samples were collected via
finger prick for three malaria tests:
– QBC-test: 50-65 μl of blood was drawn into an
acridine orange-coated heparinized capillary tube,
handled according to the manufacturers’
recommendations [35], and read on site,
– HRP2-based RDT (Palutop®, from the Alldiag,
Strasbourg, France): one drop of blood with solvent
was read on site under oil immersion after 15
minutes according to the manufacturers’
recommendations [36],
– Thick and thin blood films were used to establish a
reference diagnosis: one slide with four blood drops
[three for the Giemsa-stained thick film (GTF) and
one for the thin blood film]. These slides were
coloured once a week with Giemsa at the Centre
National de Recherche et de Formation sur le
Paludisme in Ouagadougou, a public health research
centre in Ouagadougou. The slides were read at the
end of the study following the Centre’s protocol: the
slides were examined by two experienced
researchers (and possibly by a third expert in case of
disagreement between the two. Parasitaemia was
calculated on the thick film by the number of
trophozoites for 10 leucocytes, and the species was
determined on the thin film when the thick film was
positive. About 10% of these slides (taken at
random) and all of the conflict cases (in which one
of the three tests showed a different result from the
other two) were re-read (complete reading of the
thick and thin films) at the Institut de Parasitologie
et de Pathologie Tropicale de Strasbourg in order to
establish a final reference diagnosis.
Diagnosis and patient management
This study was non interventional. Since the final refer-
ence diagnosis was not known at the time of consult-
ation, the QBC-test result was taken into account so as
to determine whether to treat the patients for malaria,
as the physicians of the CMS usually did. When the
QBC-test was positive, patients were treated according
to national guidelines:
– Non-complicated malaria: association of
lumefantrine (120 mg) and artemether (20 mg),
6 times four tablets every 12 hours;
– Complicated malaria [37]: 8 mg/kg of intravenous
quinine every 8 hours, with an initial bolus of 16
mg/kg and relay with oral quinine 48 hours after the
last febrile seizure for 10 days of treatment, at the
same dosage.
Table 1 Fever aetiologies in 306 adults from non-malaria
endemic countries living or travelling in Burkina Faso
Undefined fever
With acute digestive symptomatology 87 (28.4%)
Without acute digestive symptomatology 70 (22.9%)
Malaria 69 (22.6%)
Pneumonia 37 (12.1%)
ENT infections 35 (7.8%)
Pyelonephritis 4 (1.3%)
Erysipelas 4 (1.3%)
Total 306 (100%)
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Figure 1 Number of malaria cases in adults from non-Malaria
endemic countries living or travelling in Burkina Faso who
presented with acute fever during the next year.
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tions were eventually carried out by the physicians of
the CMS, according to the clinical status, to determine
the aetiology of the observed febrile syndrome, such as
urinary cultures for pyelonephritis and chest x-rays for
pneumonia. No anti-malarial treatment was initiated
without a positive QBC test.
Data analysis
For statistical analysis, Chi-squares (χ2) or Student-t-tests
(t-test) were used, as appropriate. Bilateral analysis was
computed, and the significance level was set at 0.05.
Results
Over a one-year period, informed consent was obtained
from 306 patients consulting for febrile syndrome: 149
males and 157 females. Patients were separated into two
groups according to the amount of time spent in Burkina
Faso: patients that stayed longer than three months were
labelled “resident” (202) and those that stayed less than
three months were labelled “traveller” (104).
The distribution varied throughout the year. “Travellers”
were most often present (and, therefore, attended medical
consultation) during summer and Christmas vacations
or during the international film festival in February
(FESPACO), while “residents” were present year-round.
Two peaks of consultation for febrile syndrome were
noted in the “resident” population: the first in October,
just after the rainy season, and the second one in February,
before the start of the hot season.
Fever on examination
We first evaluated antipyretics as potentially confounding
factor, following the Mantel-Haenszel method. The
stratificated ORs of patients with and without antipyretics
were compared to determine if an effect modification or
interaction was indeed taking place between those two
variables. There was no statistical interaction neither with
patients considered “febrile on examination” (OR O,91,
[0,47-1,74]) nor with malaria (OR 0,76 [0,36-1,62]).
Of the 57 patients who were “febrile on examination”
(patients with an uncorrected axillary temperature over
38.0°C), only 22 had malaria (38.6%), which is a signifi-
cantly higher percentage than that of the 47 malaria
cases (18.9%) among the 249 “non-febrile patients on
examination” (χ2, p < 0.001).
Malaria and other aetiologies of fever throughout the year
Aetiologies of fever are reported in Table 1. Of the 306
patients, 69 were diagnosed with malaria (22.6%): 67
P. falciparum (97.1%) including two mixed infections
with Plasmodium malariae, and one with P. malariae
only. In the last case, no species could be determined,
due to an extremely low parasitaemia (post-treatmentdiagnosis, with very low positive GTF and negative thin
blood film).
Most malaria cases (88.4% of diagnoses [Figure 1]) were
concentrated between July and December, with a peak in
October-November, approximately one month after the
precipitous peak of the rainy season. The maximal malaria
prevalence (nearly 50%) was in October-November among
both “travellers” and “residents” (Figure 2).
In January, three patients diagnosed with malaria re-
ported having travelled outside Burkina Faso in the pre-
vious month (two to Ghana and one to Mali near the
river Niger), as well as one in February (Mali).
Malaria and chemoprophylaxis
Following the national and international recommenda-
tions, a long-term prophylaxis was not recommended to
the residents, but only 69% of the travellers correctly
took one. Only one of them (a “traveller”) who took
chemoprophylaxis correctly suffered from malaria
(Table 2). This young, 20-year-old patient took a prophy-
laxis based on a chloroquine and proguanil association
in accordance with current recommendations [38] (level
2 in 2006) of the Institut de Veille Sanitaire, the French
Ju
ly
Au
gu
st
 
Se
pt
em
be
r
Oc
to
be
r
No
ve
m
be
r
De
ce
m
be
r
Ja
nu
ar
y
Fe
br
ua
ry
Ma
rc
h
Ap
ril
Ma
y
Ju
neJu
ly
0
50
100
150
200
250
0
20
40
60
Travelers
Resident
Precipitation
P
re
ci
p
it
at
io
n
 m
m
%
 o
f m
alaria in
 feb
rile p
atien
ts
Figure 2 Malaria prevalence in adults from non-Malaria
endemic countries living or travelling in Burkina Faso and
presenting with acute fever.
Table 3 Symptoms associated with fevers in 306 adults
travelling in Burkina Faso, regardless of the link to
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ern part of Burkina Faso that borders the Ivory Coast. A
higher anti-malarial drug resistance was recorded in Ivory
Coast and a different prophylaxis is recommended (level
3, mefloquine or a proguanil and atovaquone association).
Clinical signs and their association with malaria
Five categories for patient symptoms were determinate:
digestive (vomiting, abdominal pain, diarrhoea, etc.), ear-
nose-throat (ENT) (rhinitis, pharyngitis, odynophagia…),
respiratory, urinary, and cutaneous. Those that did not
correspond with any of these categories were considered
“isolated fevers”. Table 3 shows the signs’ prevalence by
malaria cases and non-malaria cases.
The performance of the best symptom or association
of symptoms for malaria diagnosis in this study is dis-
played on Table 4. Isolated fever was the most frequentTable 2 Malaria prevalence according to the length of
stay and malaria chemoprophylaxis in 306 febrile adults
from non-Malaria endemic countries living or travelling
in Burkina Faso
Non malaria Malaria
Journeys under
3 months
With adapted and well-taken
chemoprophylaxis
71 1
Malaria prevalence 1.4%
Without appropriate
chemoprophylaxis
21 11
Malaria prevalence 34.4%
Journeys over
3 months
With adapted and well-taken
chemoprophylaxis
27 0
Malaria prevalence 0%
Without appropriate
chemoprophylaxis
118 57
Malaria prevalence 32.6%clinical sign for malaria (78.3%), but more than half of
these isolated fevers were related to another origin. There
were significantly more fevers on clinical examination in
the malaria group.
Malaria diagnosis
To predict the performance of on-the-spot, available
tests, namely the HRP2- based RDT and QBC-tests,
these tests were performed in addition to thick and thin
blood film examinations for each patient. The results of
these three tests were coincident in 94% of the patients
(289/306). The results of the tests’ diagnosis perform-
ance are summarized in Table 4.
Discussion
Malaria diagnosis
The QBC-test is quick and easy to use: every physician
was trained for approximately one hour, and the test’s
complete implementation took less than 10 minutes.
The main inconvenience was the material: the initial in-
vestment is important (centrifuge, microscope with oil
immersion). In a clinical laboratory in Ouagadougou in
2013, the cost of a QBC-test for the patient is between
1,500 and 2,000 XOF (2–3 €); this not much more ex-
pensive than for a GTF who will cost 1,000 to 1,500
XOF (1,5 to 2 €) [39]. The logistics (management of
colouring agents and colourings) are less binding compar-
ing to a GTF, because every test can be analysed individu-
ally. The Becton-Dickinson company, which developed
this technique, stopped marketing the test’s in 2006 [40],
but the assay commercialization was taken over by QBC-
Diagnostics, which continues to develop new and lessmalaria
Symptom
Non-malaria
patients
Malaria
patients
Total
237 69 306
Isolated fever 68 54 122
Prevalence 28.7% 78.3% 39.9%
Digestive symptoms 88 9 97
Prevalence 37.1% 13.0% 31.7%
ENT symptoms 37 5 42
Prevalence 15.2% 7.3% 13.7%
Respiratory symptoms 36 1 37
Prevalence 15.2% 1.5% 12.1%
Urinary symptoms 4 0 4
Prevalence 1.7% 1.3%
Cutaneous symptoms 4
0
4
Prevalence 1.7% 1.3%
Table 4 Statistical value of clinical signs, association of clinical signs and malaria tests (QBC and HRP2-based RDT) for
the diagnosis of malaria, according to the results of the thick and thin Giemsa-stained blood films, considered to be
the gold standard method (with 95% confidence intervals for sensibility and specificity)
Sensibility Specificity Positive predictive
value
Negative predictive
value
Isolated fever
78.3% 71.3%
44.3% 91.9%
[68.5 – 88.0] [65.6 – 77.1]
Fever present on examination 31.9% 85.2%
38.6% 81.1%
[20.9 – 42.9] [80.7 – 89.8]
Isolated fever present on examination 26.1% 96.2%
66.7% 81.7%
[15.7 – 36.5] [93.8 – 98.6]
Digestive symptoms 13.0% 62.9%
9.3% 71.3%
[5.1 – 21.0] [57.2 – 69.4]
QBC 98.6% 99.6%
98.6% 99.6%
[9.7 – 100] [98.8 – 100]
HRP2 84.0% 98.0%
92.0% 95.0%
(for P. falciparum) [75.4 – 92.7] [96.7 – 99.9]
Schrot-Sanyan et al. Malaria Journal 2013, 12:270 Page 5 of 8
http://www.malariajournal.com/content/12/1/270cumbersome devices [41]. The capillary tube enables a
blood cell count obtained in a few minutes, which may be
especially helpful when the fevers are unrelated to malaria,
as observed in approximately 80% of cases.
The QBC-test offers more than a reliable performance:
sensitivity and positive predictive value over 98%, and
specificity and negative positive value over 99%. These
figures are much superior to those found in the local
GTF-using laboratories [27-29]: there was only one
false-positive and one false-negative, both observed during
post-treatment. However, the test did not allow identifying
the species in the only case of P. malariae infection. This
likely caused overtreatment via artemisinin-derivatives
when chloroquine treatment would have been sufficient.
Nonetheless, the benefit/risk balance remains much more
favourable for the QBC-test, when more than 97% of the
malaria cases were due to P. falciparum.
RDT was significantly overall less sensitive than the
QBC, as confirmed by several studies [42,43]: the num-
ber of false-negatives by antigen HRP2 detection is high
(15.9%). RDT remains useful only under conditions in
which it is the only test available, and the results must
be interpreted carefully: a negative test must be repeated
in the absence of clinical improvement. A RDT costs be-
tween 4,000 to 10,000 XOF (6 to 15 €) in Ouagadougou
in 2013.
The RDT remains an asset in retrospective diagnosis,
when PCR is not available: 10% of our patients, prior to
fever consultation, had already undergone malaria treat-
ment. In one of these cases, QBC did not diagnose ma-
laria, whereas the RDT would have been able to make
the diagnosis. Four other patients, who had also already
undergone treatment, exhibited negative direct micro-
scopic test (QBC and GTF), along with a positive RDT;we wonder whether these were authentic malaria cases,
though masked by treatment. This would have changed
patient management: in the case of proven malaria,
post-treatment observation would be increased, and in
the case of a negative test, we would direct our search
towards another aetiology.
Malaria prevalence and other aetiologies of fever
Malaria was the second highest fever diagnosis behind
unexplained fevers, with a prevalence from 22.6%. The
rate among African residents in Ouagadougou was not
different, and was between 17% and 20% [44]. The mal-
aria prevalence among “residents” with febrile syndrome
was 28.2% on average, which was significantly higher
than that among “travellers” (11.5%, χ2, p < 0.001). With
respect to the malaria cases, 82.6% were diagnosed
among “residents”, even though they represented only
66% of total patients.
Pneumonias were the third aetiology of fever (13.8%).
They were especially prevalent at the beginning of the
hot season, when the Harmattan, a very dry, hot, and
sandy wind blows from the desert. Thus, the Harmattan
may account for the second peak in February fever dis-
tribution. This phenomena, which is well documented in
Burkina Faso [44], also facilitates meningococcal diffu-
sion. For Africans living in Ouagadougou, pneumonias
are the first aetiology of fever and represent 27.6% of all
fevers [44].
Chemoprophylaxis
Only one malaria case was recorded in a “traveller”
under appropriate and successfully administered chemo-
prophylaxis, according to the current French recommen-
dations in 2006. These recommendations have since
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69% of the travellers correctly took one.
Clinical signs associated to the malaria
With a malaria prevalence of only 22.6%, a systematic
treatment by febrile syndrome such as “Emergency
Standby Treatment”, as recommended for travellers go-
ing to remote places where access to medical care is un-
likely to be within 24 hours, will lead in Burkina Faso to
77.4% of unnecessary treatments. A clinical diagnosis
based on isolated fever, with a negative predictive value
(NPV) of 91.9% and a positive predictive value (PPV)
of 44% (Table 4), would result in 56% of unnecessary
treatments and 22% of undiagnosed malaria infections.
Such a clinical diagnosis would cause a diagnosis delay
with potentially serious consequences. Other important
clinical signs or combinations of signs do not allow us to
justify a presumptive treatment. Isolated fever, present at
the time of the examination, would be a strong factor of
“suspicion of malaria” with a PPV of 66.7%.
A reliable and systematic test for malaria diagnosis is
necessary to judiciously dispense malaria therapies to a
population of non-immune adults staying in an endemicAdult with
(or suspic
sahelian c
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Figure 3 Management recommendation for febrile adults from non-maarea. The low malaria prevalence among fevers, as well
as the clinical examinations’ lack of sensibility and speci-
ficity, do not justify the risk of severe and unwanted
side-effects, treatment resistance, heavy financial bur-
dens associated with using new molecules, such as
artemisinin-derivatives [24,45,46], as well as delays in
the diagnosis of other serious diseases [47-50].
Based on this data, Figure 3 attempted to define a de-
cision algorithm in order to help physicians working in
Burkina Faso.
Conclusions
The two most frequent fever pathologies found in adults
travelling to Ouagadougou, namely digestive tract infec-
tions and malaria, should be the object of information
and preventative measures prior to departure. For mal-
aria, chemoprophylaxis proved to be effective in this
study. However, only 69% of short-stay patients effect-
ively took chemoprophylaxis. Travel to high-risk areas is
increasing, and it is becoming increasingly important for
physicians to provide good advice prior to departure.
At the facility, all patients with fever or “suspicion of
fever” must systematically be evaluated with a reliable fever 
ion) in
ountry
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Malaria treatment
laria endemic countries living or travelling in Sahelian countries.
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http://www.malariajournal.com/content/12/1/270malaria test prior to treatment. In this Sahelian context,
the QBC seems to be the most reliable diagnosis test;
the RDT still remains a feasible testing option, especially
in the case of prior treatment. However, since malaria
has an especially low prevalence in dry season, other ae-
tiologies, such as pneumonias, must be considered with-
out delay.
Abbreviations
χ2: Chi-squared test; ENT: ear, nose, and throat; GTF: Giemsa-stained thick
film; NPV: Negative predictive value; OR: odds ratio; PPV: Positive predictive
value; QBC: Quantitative Buffy Coat; RDT: Rapid Diagnostic Test; t-test:
Student’s test.
Competing interests
The authors have no conflict of interest to declare.
Authors’ contributions
SSS and SGP with help of EC participated in the study design and collected
the samples; SSS conducted the review and analysis and wrote the first draft
of the manuscript. AAB and SBS performed the GTF examination. All authors
took part in the preparation and final approval of the manuscript.
Acknowledgements
The authors are very grateful to CMS personnel for their help and support
with this study, especially to Chantal Kam, head nurse, Adele, the essential
secretary, and all the others physicians and nurses. The authors also would
like to thank the Centre National de Recherche et de Formation sur le
Paludisme de Ouagadougou personnel for their help and daily cheer!
Received: 15 February 2013 Accepted: 11 June 2013
Published: 2 August 2013
References
1. Snow RW, Craig MH, Deichmann U, le Sueur D: A preliminary continental
risk map for malaria mortality among African children. Parasitol Today
1999, 15:99–104.
2. Robert V, Chippaux J, Dioamdé L: Le Paludisme en Afrique de l’Ouest: études
entomologiques et épidémiologiques en zone rizicole et en milieu urbain. IRD
Editions: ORSTOM; 1991.
3. Ouédraogo A, Tiono AB, Diarra A, Sanon S, Yaro JB, Ouedraogo E,
Bougouma EC, Soulama I, Gansané A, Ouedraogo A, Konate AT, Nebie I,
Watson NL, Sanza M, Dube TJT, Sirima SB: Malaria morbidity in high and
seasonal malaria transmission area of Burkina Faso. PLoS One 2013,
8:e50036.
4. WHO: Global Malaria Programme, World malaria report 2012. Geneva: World
Health Organization; 2012.
5. Snow RW, Craig M, Deichmann U, Marsh K: Estimating mortality, morbidity
and disability due to malaria among Africa’s non-pregnant population.
Bull World Health Organ 1999, 77:624–640.
6. Becher H, Müller O, Jahn A, Gbangou A, Kynast-Wolf G, Kouyaté B: Risk
factors of infant and child mortality in rural Burkina Faso. Bull World
Health Organ 2004, 82:265–273.
7. Direction générale de l’information et des statistiques sanitaires: Annuaire
statistique 2009 de la santé. Ouagadougou, Burkina Faso: Ministère de la
Santé; 2010:191.
8. Communauté française La France au Burkina Faso. [http://www.ambafrance-
bf.org/Communaute-francaise]
9. Romi R, Boccolini D, D’Amato S, Cenci C, Peragallo M, D’Ancona F, Pompa
MG, Majori G: Incidence of malaria and risk factors in Italian travelers to
malaria endemic countries. Travel Med Infect Dis 2010, 8:144–154.
10. Askling HH, Nilsson J, Tegnell A, Janzon R, Ekdahl K: Malaria risk in
travelers. Emerg Infect Dis 2005, 11:436–441.
11. Bottieau E, Clerinx J, Schrooten W, Van den Enden E, Wouters R, Van
Esbroeck M, Vervoort T, Demey H, Colebunders R, Van Gompel A, Van den
Ende J: Etiology and outcome of fever after a stay in the tropics.
Arch Intern Med 2006, 166:1642–1648.
12. Bottieau E, Clerinx J, Van den Enden E, Van Esbroeck M, Colebunders R, Van
Gompel A, Van den Ende J: Fever after a stay in the tropics: diagnosticpredictors of the leading tropical conditions. Medicine (Baltimore) 2007,
86:18–25.
13. Siikamäki HM, Kivelä PS, Sipilä PN, Kettunen A, Kainulainen MK, Ollgren JP,
Kantele A: Fever in travelers returning from malaria-endemic areas: don’t
look for malaria only. J Travel Med 2011, 18:239–244.
14. Wilson ME, Weld LH, Boggild A, Keystone JS, Kain KC, von Sonnenburg F,
Schwartz E: Fever in returned travelers: results from the GeoSentinel
Surveillance Network. Clin Infect Dis 2007, 44:1560–1568.
15. Kortepeter MG, Seaworth BJ, Tasker SA, Burgess TH, Coldren RL, Aronson NE:
Health care workers and researchers traveling to developing-world
clinical settings: disease transmission risk and mitigation. Clin Infect Dis
2010, 51:1298–1305.
16. Odolini S, Parola P, Gkrania-Klotsas E, Caumes E, Schlagenhauf P, López-Vélez R,
Burchard G-D, Santos-O’Connor F, Weld L, von Sonnenburg F, Field V, de Vries
P, Jensenius M, Loutan L, Castelli F: Travel-related imported infections in
Europe, EuroTravNet 2009. Clin Microbiol Infect 2012, 18:468–474.
17. Johnston V, Stockley JM, Dockrell D, Warrell D, Bailey R, Pasvol G, Klein J,
Ustianowski A, Jones M, Beeching NJ, Brown M, Chapman ALN, Sanderson
F, Whitty CJM: Fever in returned travellers presenting in the United
Kingdom: recommendations for investigation and initial management.
J Infect 2009, 59:1–18.
18. Leggat PA: Assessment of febrile illness in the returned traveller.
Aust Fam Physician 2007, 36:328–332.
19. Lo Re V 3rd, Gluckman SJ: Fever in the returned traveler. Am Fam
Physician 2003, 68:1343–1350.
20. Blair JE: Evaluation of fever in the international traveler. Unwanted
“souvenir” can have many causes. Postgrad Med 2004, 116:13–20. 29.
21. Ohrt C, Ohrt C, Purnomo OC, Sutamihardja MA, Tang D, Kain KC: Impact of
microscopy error on estimates of protective efficacy in malaria-
prevention trials. J Infect Dis 2002, 186:540–546.
22. Tagbo O, Henrietta UO: Comparison of clinical, microscopic and rapid
diagnostic test methods in the diagnosis of Plasmodium falciparum
malaria in Enugu, Nigeria. Niger Postgrad Med J 2007, 14:285–289.
23. Matta S, Kantharia SL, Desai VK: Malaria diagnosis in private laboratories of
Surat city: a laboratory based study. J Vector Borne Dis 2004, 41:76–79.
24. Zurovac D, Larson BA, Akhwale W, Snow RW: The financial and clinical
implications of adult malaria diagnosis using microscopy in Kenya.
Trop Med Int Health 2006, 11:1185–1194.
25. Dini L, Frean J: Quality assessment of malaria laboratory diagnosis in
South Africa. Trans R Soc Trop Med Hyg 2003, 97:675–677.
26. Kilian AH, Metzger WG, Mutschelknauss EJ, Kabagambe G, Langi P, Korte R,
von Sonnenburg F: Reliability of malaria microscopy in epidemiological
studies: results of quality control. Trop Med Int Health 2000, 5:3–8.
27. Beljaev AE, Brohult JA, Sharma GK, Haque MA, Samantaray KC: Studies on
the detection of malaria at primary health centres. Part I. Reliability of
parasitological diagnosis by decentralized laboratories. Indian J Malariol
1985, 22:85–103.
28. Collier JA, Longmore JM: The reliability of the microscopic diagnosis of
malaria in the field and in the laboratory. Ann Trop Med Parasitol 1983,
77:113–117.
29. Okell LC, Ghani AC, Lyons E, Drakeley CJ: Submicroscopic infection in
Plasmodium falciparum-endemic populations: a systematic review and
meta-analysis. J Infect Dis 2009, 200:1509–1517.
30. Raghavan K: Statistical considerations in the microscopical diagnosis of
malaria, with special reference to the role of cross-checking. Bull World
Health Organ 1966, 34:788.
31. Ochola L, Vounatsou P, Smith T, Mabaso M, Newton C: The reliability of
diagnostic techniques in the diagnosis and management of malaria in
the absence of a gold standard. Lancet Infect Dis 2006, 6:582–588.
32. Schlagenhauf P, Petersen E: Standby emergency treatment of malaria in
travelers: experience to date and new developments. Expert Rev Anti
Infect Ther 2012, 10:537–546.
33. Chandramohan D, Carneiro I, Kavishwar A, Brugha R, Desai V, Greenwood B:
A clinical algorithm for the diagnosis of malaria: results of an evaluation
in an area of low endemicity. Trop Med Int Health 2001, 6:505–510.
34. Grimes DA, Schulz KF: Refining clinical diagnosis with likelihood ratios.
Lancet 2005, 365:1500–1505.
35. Beckton Dickinson and Company: Manuel d’utilisation du QBC-Malaria-Test.
Grenoble; 1993.
36. AllDiag: Manuel d’Utilisation version 3 du Palutop and Palutop 4+. Strasbourg;
2003.
Schrot-Sanyan et al. Malaria Journal 2013, 12:270 Page 8 of 8
http://www.malariajournal.com/content/12/1/27037. World Health Organization: Communicable Diseases Cluster: Severe
falciparum malaria. Trans R Soc Trop Med Hyg 2000, 94(1):S1–S90.
38. BEH: Santé des voyageurs et recommandations sanitaires 2006, Bulletin
épidémiologique hebdomadaire, Institut de veille sanitaire. 2006:153–176.
39. Laboratoire d’Analyses Médicales du Centre, Ougagdougou, Burkina Faso.
[http://labocentre.bf/spip.php?page=article&id_article=8]
40. De Pina JJ, Garnotel E, Hance P, Vedy S, Rogier C, Morillon M: Diagnostic du
paludisme d’importation en France. Médecine et Maladies Infectieuses 2007,
37:710–715.
41. QBC Diagnostics, Inc: [www.qbcdiagnostics.com]
42. Moody A: Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev
2002, 15:66–78.
43. Bell D, Wongsrichanalai C, Barnwell JW: Ensuring quality and access for
malaria diagnosis: how can it be achieved? Nat Rev Microbiol 2006,
4:S7–S20.
44. Coulibaly C, Guiguemde T, Lamizana L, Ouedraogo J, Dabiret E: La part du
paludisme dans les affections fébriles en milieu urbain de Ouagadougou
(Burkina Faso, Afrique de l’Ouest). Ann Soc belge Méd trop 1991, 71:5–10.
45. World Health Organisation: Recent WHO Publications. Bull World Health
Organ 1994, 72:525–532.
46. Jonkman A, Chibwe RA, Khoromana CO, Liabunya UL, Chaponda ME,
Kandiero GE, Molyneux ME, Taylor TE: Cost-saving through microscopy-
based versus presumptive diagnosis of malaria in adult outpatients in
Malawi. Bull World Health Organ 1995, 73:223–227.
47. English M, Punt J, Mwangi I, McHugh K, Marsh K: Clinical overlap between
malaria and severe pneumonia in Africa children in hospital. Trans R Soc
Trop Med Hyg 1996, 90:658–662.
48. Gwer S, Newton C, Berkley J: Overdiagnosis and comorbidity of severe
malaria in African children: a guide for clinicians. AmJTrop Med Hyg 2007,
77:6–13.
49. Reyburn H: Overdiagnosis of malaria in patients with severe febrile
illness in Tanzania: a prospective study. BMJ 2004, 329:1212.
50. Van Dillen J, De Jager AJ, De Jong I, Wendte JF: Overdiagnosis of malaria
in hospitalized patients in Namibia. Trop Doct 2007, 37:185–186.
doi:10.1186/1475-2875-12-270
Cite this article as: Schrot-Sanyan et al.: Malaria relevance and diagnosis
in febrile Burkina Faso travellers: a prospective study. Malaria Journal
2013 12:270.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
